Tysabri ইউরোপীয় ইউনিয়ন - ফিনিশ - EMA (European Medicines Agency)

tysabri

biogen netherlands b.v. - natalitsumabin - multippeliskleroosi - selektiiviset immunosuppressantit - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ja 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Alphagan 0,2 % (2 mg/ml) silmätipat, liuos ফিনল্যান্ড - ফিনিশ - Fimea (Suomen lääkevirasto)

alphagan 0,2 % (2 mg/ml) silmätipat, liuos

abbvie oy - brimonidine tartrate - silmätipat, liuos - 0,2 % (2 mg/ml) - brimonidiini

Mydriasert 0.28 mg / 5.4 mg silmälamelli ফিনল্যান্ড - ফিনিশ - Fimea (Suomen lääkevirasto)

mydriasert 0.28 mg / 5.4 mg silmälamelli

laboratoires thea - phenylephrine hydrochloride, tropicamide - silmälamelli - 0.28 mg / 5.4 mg - tropikamidi

Oftastad 50 mikrog/ml silmätipat, liuos ফিনল্যান্ড - ফিনিশ - Fimea (Suomen lääkevirasto)

oftastad 50 mikrog/ml silmätipat, liuos

stada arzneimittel ag - latanoprost - silmätipat, liuos - 50 mikrog/ml - latanoprosti

LENCYA 30 mg tabletti, kalvopäällysteinen ফিনল্যান্ড - ফিনিশ - Fimea (Suomen lääkevirasto)

lencya 30 mg tabletti, kalvopäällysteinen

sandoz a/s sandoz a/s - ulipristali acetas - tabletti, kalvopäällysteinen - 30 mg - ulipristaali